title: Healthcare costs and long-term outcomes after acute respiratory distress syndrome: A phase III trial of inhaled nitric oxide.
abstract: OBJECTIVE
  To determine the costs and long-term outcomes of acute respiratory distress syndrome (ARDS) in previously healthy adults. To determine whether treatment with inhaled nitric oxide affects these costs and outcomes.
  
  
  METHODS
  One-year follow-up of a randomized trial of inhaled nitric oxide. Hospital bills were collected, and follow-up was performed at hospital discharge, 6 months, and 1 year.
  
  
  METHODS
  Forty-six U.S. centers.
  
  
  METHODS
  Three hundred and eighty-five previously healthy adults with ARDS.
  
  
  METHODS
  Subjects were randomized to 5 ppm inhaled nitric oxide or placebo gas.
  
  
  RESULTS
  One-year survival was 67.8%, with no difference by treatment arm (67.3% vs. 68.3% for inhaled nitric oxide vs. placebo, p = .71). Hospital costs from enrollment to discharge were high and similar in the inhaled nitric oxide and placebo arms ($48,500 vs. $47,800, p = 0.8). There were also no differences in length of stay or Therapeutic Intervention Scoring System points. Almost half (43.4%) of subjects were discharged to another healthcare facility or to home with professional help, and 24.1% were readmitted in 6 months, with no differences between groups. At 1 year, survivors reported low quality of life with no differences by treatment arm (Quality of Well-Being score [range 0-1], 0.61 vs. 0.64 for inhaled nitric oxide vs. placebo, p = .11) and poor function with no differences by treatment arm (32.5% returned to </=5 points of baseline Activities of Daily Living [range 0-100], 63.3% returned to </=10 points, and the remaining 36.7% suffered a mean decrement of 27 points).
  
  
  CONCLUSIONS
  ARDS, even in previously healthy adults, not only is followed by poor survival, quality of life, and function but also is associated with high costs of care and postdischarge resource use. Inhaled nitric oxide at 5 ppm had no effect on these outcomes.
authors.affiliation: CRISMA Laboratory (Clinical Research, Investigation, and Systems Modeling of Acute Illness), Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
authors.forename: Derek C
authors.initials: DC
authors.lastname: Angus
authors.forename: Gilles
authors.initials: G
authors.lastname: Clermont
authors.forename: Walter T
authors.initials: WT
authors.lastname: Linde-Zwirble
authors.forename: Amjad A
authors.initials: AA
authors.lastname: Musthafa
authors.forename: Tony T
authors.initials: TT
authors.lastname: Dremsizov
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Lidicker
authors.forename: Judith R
authors.initials: JR
authors.lastname: Lave
mesh_terms: D000280:Administration, Inhalation; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D017048:Health Care Costs; D017721:Hospital Costs; D006801:Humans; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D011788:Quality of Life; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000191:economics*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D001993:Bronchodilator Agents; D009569:Nitric Oxide